Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer

Anticancer Research

Volumn 27, Issue 6 C, 2007, Pages 4425-4429

  Mencoboni, Manlio ^a   Bergaglio, M ^a   Serra, M ^a   Ivaldi, G P ^a   Tredici, S ^a   Racchi, O ^a   Rebella, L ^a   Galbusera, V ^a   Grosso, M ^a   Faravelli, B ^a  

^a VILLA SCASSI HOSPITAL   (Italy)

Author keywords

Gefitinib; Maintenance therapy; NSCLC

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FOLLICULITIS; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; SURVIVAL ANALYSIS;

EID: 37549005527     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cascone T, Morelli MP and Ciardiello F: Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. Ann Oncol 17(Suppl 2): 46-48, 2006.
2. Hatzidaki D, Agelaki S, Mavroudis D, Vlachonikolis I, Alegakis A and Georgoulias V: Lung Cancer Group of the Hellenic Oncology Research Group. A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-smallcell lung cancer. Clin Lung Cancer 8(1): 49-55, 2006.
3. Rosell R, Cecere F, Cognetti F, Cuello M, Sanchez JM, Taron M, Reguart N and Jablons D: Future directions in the second-line treatment of non-small cell lung cancer. Semin Oncol 33(1 Suppt 1): S45-51, 2006.
4. De Marinis F, De Santis S and De Petris L: Second-line chemotherapy for non-small cell lung cancer. Ann Oncol 17(Suppl 5): 68-71, 2006.
5. Lynch T Jr and Kim E: Optimizing chemotherapy and targeted agent combinations in NSCLC. Lung Cancer 50(Suppl 2): 25-32, 2005.
6. Scagliotti G: An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer. Expert Opin Pharmacother 6(16): 2855-2866, 2005.
7. Cufer T, Vrdoljak E, Gaafar R, Erensoy I and Pemberton K: SIGN Study Group. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small cell lung cancer. Anticancer Drugs 17(4): 401-409, 2006.
8. Kaplan EL and Meier P: Nonparametric estimation of incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
9. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L and Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9): 1589-1597, 2004.
10. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregore V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr and Varella-Garcia M: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9): 643-655, 2005.
11. Blackhall F, Ranson M and Thatcher N: Where next for gefitinib in patients with lung cancer? Lancet Oncol 7(6): 499-507, 2006.
12. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) (corrected) J Clin Oncol 21(12): 2237-2246, 2003.
13. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ and Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16): 2149-2158, 2003.
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P and Seymour L; National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353(2): 123-132, 2005.
15. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P and Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22(16): 3238-3247, 2004.
16. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A and Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 22(5): 777-784, 2004.
17. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A and Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 22(5): 785-794, 2004.
18. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (IRESSA Survival Evaluation in Lung Cancer). Lance. 366(9496): 1527-1537, 2005.
19. Kelly K, Gaspar L and Chansky K: Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and IRESSA/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. Proc Am Soc Clin Oncol 23: abstr 7058, 2005.
20. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y and Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18(10): 2095-2103, 2000.
21. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kaiman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F and Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18(12): 2354-2362, 2000.
22. Camps C, Caballero C, Blasco A, Safont MJ, Berrocal A, Garde J, Juarez A, Sirera R and Bremnes RM: Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: efficacy and tolerability. Anticancer Res 25(6C): 4611-4614, 2005.
23. De Petris L, Migliorino MR, Ceribelli A, Martelli O, Di Molfetta M, Mancuso A, De Santis S, Di Salvia R and De Marinis F: Docetaxel administered every two weeks as second-line chemotherapy for advanced non-small cell lung cancer: a phase II study. Anticancer Res 25(6C): 4713-4717, 2005.
24. Veslemes M, Antoniou D, Georgatou N, Giamboudakis P, Dimitroulis J, Katis K and Stathopoulos GP: Phase II study of cisplatin-combined schedules as second-line chemotherapy in patients with non-small cell lung cancer. Anticancer Res 25(4): 2991-2996, 2005.
25. Ostoros G, Harisi R, Kovacs G, Horti J, Geczi L, Szondy K, Orosz M, Ferenczi E, Ruby E and Dome B: Inhibition of EGFR tyrosine-kinase in NSCLC treatment: the Hungarian experience with gefitinib in the context of an expanded access programme. Anticancer Res 25(6C): 4759-4762, 2005.